GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2008

Invitrogen to Leverage Certain hESC Patents from WARF to Develop Research Technology

  • Invitrogen inked a license agreement with Wisconsin Alumni Research Foundation (WARF) related to certain human embryonic stem cell (hESC) patents. The company gains the right to work with karyotypically normal hESCs to develop research and drug discovery tools.

    “Invitrogen’s goal is the development of research tools that enhance the ability of scientists to work with embryonic stem cells and to enhance the utility of these cells for research and drug discovery,” according to Joydeep Goswami, vp, stem cells and regenerative medicine.

    “Having the ability to work with karyotypically normal hESCs through our license with WARF allows us to develop better technologies for research, such as more defined media and engineered stem cell lines. This agreement is another step in our strategy of pursuing advances in the high-growth area of regenerative medicine.”

    WARF reports that it has completed 24 licensing agreements for stem cell technologies with 18 companies.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?